Attovia Therapeutics raises $289 million in IPO, adding third I&I drug to market debut

Attovia Therapeutics, a biotech focused on immunology and inflammation, completed an initial public offering that raised about $289 million.

The funds will support the development of three I&I drug candidates the company is bringing to market, according to CEO Tao Fu.

This IPO marks the third straight week of new biotech listings, a milestone not seen since the winter of 2025, highlighting renewed investor interest in the sector.